Atracurium
- Atc Codes:M03AC04
- CAS Codes:64228-81-5
- PHARMGKB ID:64228-81-5
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Atracurium, Tracrium; Belgium: Tracrium; Bulgaria: Tracrium; Cyprus: Tracrium; Czech Republic: Tracrium; Estonia: Tracrium; France: Atracurium, Tracrium; Germany: Atracurium, Tracrium; Greece: Tracrium; Hungary: Tracrium; Ireland: Atracurium; Italy: Acurmil, Atracurio, Atracurium, Tracrium; Latvia: Tracrium; Lithuania: Tracrium; Luxembourg: Tracrium; Malta: Tracrium; Netherlands: Atracurium, Tracrium; Poland: Tracrium; Portugal: Tracrium; Romania: Tracrium; Slovakia: Tracrium; Slovenia: Tracrium; Spain: Atracurio, Tracrium; Sweden: Atracurium, Tracrium; UK: Atracurium, Tracrium.
North America
Canada: Atracurium; USA: Atracurium, Tracrium.
Latin America
Argentina: Atracurio, Atracurium, Gelolagar, Tracrium, Tracurix, Tracuron; Brazil: Abbottracurium, Atracúrio, Tracrium, Tracur; Mexico: Relatrac, Trablok, Tracrium.
Drug combinations
Chemistry
Atracurium Besylate: C~65~H~82~N~2~O~18~S~2~. Mw: 1243.48. (1) Isoquinolinium, 2,2′-[1,5-pentanediylbis[oxy(3-oxo-3,1-propanediyl)]]bis[1-[(3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-, dibenzenesulfonate; (2) 2-(2-Carboxyethyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-veratrylisoquinolinium benzenesulfonate, pentamethylene ester. CAS-64228-81-5 (1983).
Pharmacologic Category
Skeletal Muscle Relaxants; Neuromuscular Blocking Agents, Nondepolarizing. (ATC-Code: M03AC04).
Mechanism of action
Blocks neural transmission at the myoneural junction by binding with cholinergic receptor sites.
Therapeutic use
Endotracheal intubation and relaxation of skeletal muscles during surgery (adjunct to general anesthesia). Mechanical ventilation in intensive care unit.
Pregnancy and lactiation implications
Use with caution during pregnancy or lactation.
Unlabeled use
Contraindications
Hypersensitivity to atracurium or any component of the formulation.
Warnings and precautions
Bradycardia. Cross-sensitivity with other neuromuscular-blocking agents (use extreme caution in previous anaphylactic reactions). Resistance is possible in burn patients. The following conditions may antagonize neuromuscular blockade: alkalosis, hypercalcemia, demyelinating lesions, peripheral neuropathies, denervation, infection, muscle trauma, or diabetes mellitus. The following conditions may potentiate neuromuscular blockade: electrolyte abnormalities, severe hyponatremia, severe hypocalcemia, severe hypokalemia, hypermagnesemia, neuromuscular diseases, acidosis, acute intermittent porphyria, Eaton-Lambert syndrome, myasthenia gravis, renal failure, or hepatic failure. Use with caution in the elderly. Resistance may develop in immobilized patients or with chronic treatment.